How is Tirzepatide administered?
This describes how Tirzepatide is typically administered in clinical and research references, not a self-administration guide. The usual route is Subcutaneous, on a once weekly schedule, generally over open-ended, titrate over months. Specific dosing is individual and beyond general information, and human evidence for Tirzepatide is limited.
Administration at a glance (reference data)
- Route: Subcutaneous
- Schedule: Once weekly
- Cycle length: Open-ended, titrate over months
- Half-life: ~5 days
References
- Tirzepatide Once Weekly for Treatment of Obesity (SURMOUNT-1) — Jastreboff AM et al., NEJM, 2022
- Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2) — Frías et al., N Engl J Med, 2021
- Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial — Garvey et al., Lancet, 2023
Pepdex is an editorial reference, not medical advice. Peptides vary in legal and approval status by country, many are research compounds without full human safety data. Talk to a qualified clinician before starting anything.
More on Tirzepatide
Full Tirzepatide breakdownTirzepatide what it's used forTirzepatide side effectsTirzepatide mistakes to avoidTirzepatide who should avoid itTirzepatide half-lifeTirzepatide how long to workTirzepatide legal statusTirzepatide how it workstirzepatide vs semaglutideretatrutide vs tirzepatidetirzepatide vs cagrilintidevk2735 vs tirzepatideAsk the AI Coach
Last updated 2026-06-15.